1. Chemoradiotherapy-induced Cytodifferentiation in Bladder/Prostate Rhabdomyosarcoma With Genetic Downregulation of Myogenin and MyoD1 Gene Expression: A Case Study and Review of the Literature.
- Author
-
Agard H, Clark C, Massanyi E, Steele M, and McMahon D
- Subjects
- Biomarkers, Tumor analysis, Biomarkers, Tumor genetics, Biopsy methods, Diagnosis, Differential, Down-Regulation, Gene Expression, Humans, Immunohistochemistry, Infant, Male, MyoD Protein analysis, Myogenin analysis, Patient Selection, Prognosis, Cell Differentiation drug effects, Cell Differentiation radiation effects, Chemoradiotherapy adverse effects, Chemoradiotherapy methods, MyoD Protein genetics, Myogenin genetics, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology, Prostatic Neoplasms therapy, Rhabdomyosarcoma, Embryonal diagnostic imaging, Rhabdomyosarcoma, Embryonal genetics, Rhabdomyosarcoma, Embryonal pathology, Rhabdomyosarcoma, Embryonal therapy, Urinary Bladder Neoplasms diagnostic imaging, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms therapy
- Abstract
Rhabdomyosarcoma is the most common sarcoma diagnosed in childhood and adolescence, arising from the bladder/prostate in only 5%-10% of cases. Treatment-induced cytodifferention of tumor cells into mature rhabdomyoblasts has been reported following chemoradiation and is thought to suggest a more favorable outcome. We report a case of embryonal rhabdomyosarcoma of the bladder/prostate that exhibited extensive cytodifferentiation with downregulation of myogenin and MyoD1 gene expression in rhabdomyoblasts following treatment with chemoradiation therapy. The downregulation of myogenin and MyoD1 expression in rhabdomyoblasts following chemoradiation treatment has not previously been described in the literature and its significant remains uncertain., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF